Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Person › Details

Susanne Klimek (Salvator Vermögensverwaltungs GmbH)

Klimek, Susanne (Salvator Vermögensverwaltungs GmbH 201101 Managing Director)


Organisations Organisation Salvator Vermögensverwaltungs GmbH
  Former/major organisation Mologen AG
  Group Mologen (Group)
Product Product financial services

Mologen AG. (1/14/11). "Press Release: Mologen AG Is Starting an Important Business Year with a Capital Increase". Berlin.

· Increase of the capital stock by around 11 Percent

· Development of the product pipeline with additional cancer indications

· External licensing of blockbuster candidate in preparation

· Change to the Supervisory Board

Just in time for the new year, MOLOGEN AG is starting its series of activities for the creation of optimal conditions for the new fiscal year. This year, the biotechnology company is expecting much more than groundbreaking interim results from the product candidate MGN1703 which treats intestinal cancer. The company is also looking into which of the additional possible indications will expand the product pipeline; a pipeline that is already loaded with its own promising developments. The MOLOGEN AG Board of Directors has therefore decided, with the approval of the Supervisory Board, to carry out a capital increase with shareholder subscription rights.

The current capital stock of MOLOGEN AG of 11,213,348 million Euro is to be increased by around 11% to 12,459,275 million Euro by issuing up to 1,245,927 new shares. The shareholders will be granted a subscription right within the scope of a rights issue from January 17 through 31, 2011. After this time period, unpurchased new stocks will be sold to interested investors as an international private placement. The new stocks shall carry dividend rights as of January 1, 2010. The quirin bank AG in Berlin functions as a subscription agent for the new shares and is also authorized for the signing and takeover of the new shares. The subscription ratio is 9:1, i.e. every nine existing MOLOGEN shares authorizes the purchase of a new share at the purchase price. The purchase price will be determined no later than January 26, 2011 under consideration of the current market situation of the company.

The planned capital increase will occur from the authorized capital. "In accordance with our corporate culture we favor progressive capital increases which are oriented toward research advancement. Modest and tailored to needs. By doing so, we were able to secure financing for our activities at all times regardless of the market environment. The funds from this current capital increase offer us additional margin for the development of our product pipeline. After the successes with our intestinal cancer medication MGN1703, we want to take a broader view going into the future and now also clinically trial the mode of action for additional cancer indications", states Dr. Matthias Schroff, Research Chairman and Chairman of the Board of MOLOGEN AG.

Currently, four essential research projects are being carried out in various areas, which are all researched on the basis of in-house technologies. This year, MOLOGEN AG is planning to license its blockbuster candidate, the intestinal cancer medication MGN1703. In mid 2011 the interim results of the clinical phase II/III are expected, which should confirm the promising data from the clinical phase Ib, namely the evidence of the effectiveness for a significant number of patients. MOLOGEN has also made great progress with additional research projects: in December, the clinical phase I/II was started for the renal cancer medication MGN1601. Moreover, the company is developing, among other things, a DNA vaccine against hepatitis B (MGN1333), for which it has received subsidies.

Changes to the Supervisory Board

The supervisory board was regretfully informed today that its long-serving member, Ferdinand Graf von Thun und Hohenstein has resigned for health reasons. Subject to the appointment by the Register of Companies, Mrs. Susanne Klimek, managing director of Salvator Vermögensverwaltungs GmbH will follow him. Thus, as one of the long-term investors, Salvator Vermögensverwaltungs GmbH remains to be represented in this control committee. The chairman of the Supervisory Board, Dr. Mathias P. Schlichting thanks Graf von Thun und Hohenstein on behalf of the committee for his many years of service. "We can thank the participation of Graf von Thun und Hohenstein that this change signals continuity. We would be pleased to welcome Ms. Susanne Klimek to our committee in the future".

Important fiscal year

The year 2011 brings interesting prospects to MOLOGEN AG. Be it the external licensing of blockbuster candidate MGN1703, the further results of the ongoing clinical studies or the broad development of the multi-faceted market potential of the outstanding product pipeline with additional cancer indications.

The further capital increase is one of the strategic measures.


Die MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange.

(ISIN DE0006637200).

Memberships in associations:

BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.

Prof. Peter W. Huebner
Director of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50

Jörg Petraß
Tel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50

External Investor Relations
Kirchhoff Consult AG
Janina Wismar M.A.
Tel: +49 - 40 - 60 91 86 - 50
Fax: +49 - 40 - 60 91 86 - 16


This notification represents neither a request nor an offer to submit an offer for the purchase of securities. This is particularly the case in the USA and other countries or jurisdictions where an offer would be unauthorized for the submission of a bid for the purchase or sale without previous registration or authorization. The respective relevant legal provisions concerning securities for these countries and jurisdictions apply.

This notification represents neither an offer for the sale of shares without a par value attributed to the owner, nor a request to submit an offer for the purchase of shares without a par value, but rather serves solely to provide information.

Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

Record changed: 2017-04-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top